Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis
James D Chalmers, Wim Boersma, Mike Lonergan, Lata Jayaram, Megan L Crichton, Noel Karalus, Steven L Taylor, Megan L Martin, Lucy D Burr, Conroy Wong, Josje Altenburg
LANCET RESPIRATORY MEDICINE | ELSEVIER SCI LTD | Published : 2019
BACKGROUND: Bronchiectasis guidelines recommend long-term macrolide treatment for patients with three or more exacerbations per year without Pseudomonas aeruginosa infection. Randomised controlled trials suggest that long-term macrolide treatment can prevent exacerbations in adult patients with bronchiectasis, but these individual studies have been too small to do meaningful subgroup analyses. We did a systematic review and individual patient data (IPD) meta-analysis to explore macrolide benefit in subpopulations, including those in which macrolide therapy is not currently recommended. METHODS: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Scienc..View full abstract
This study was funded by the European Respiratory Society through the EMBARC2 consortium. EMBARC2 is supported by project partners Chiesi, Grifols, Insmed, Novartis, and Zambon. JDC is supported by the GSK/British Lung Foundation Chair of Respiratory Research. The BAT study was funded by Foreest Medical School and an unrestricted grant from GlaxoSmithKline. The BLESS study was funded by the Mater Adult Respiratory Research Trust Fund. The EMBRACE study was funded by the Health Research Council of New Zealand and the Auckland District Health Board Charitable Trust.